PMC3339664_01
a Retinography of the left eye reveals massive exudation within the inferior-temporal quadrant of the retina. b Horizontal and vertical (c) OCT scans (indicated as B and C, respectively, in a) centered in the fovea confirm the presence of exudative retinal detachment with macular involvement. d Fluorescein angiography shows the presence of telangiectatic vessels scattered all over the inferior-temporal retinal quadrant.
cop-0003-0123-g01.jpg
PMC3339664_01_cop-0003-0123-g01.jpg
F1
In addition, a grayish mass was observed in the inferior peripheral retina (fig. 1). Spectral-domain optical coherence tomography (SD-OCT) confirmed the presence of exudative retinal detachment with macular involvement (fig. 1). An echography showed an intraretinal mass (4.1 x 1.9 mm) located in the inferior periphery, associated with the exudative retinal detachment (fig. 1). Fluorescein angiography (fig. 1) revealed the presence of telangiectatic vessels scattered all over the inferior-temporal retinal quadrant; the peripheral inferior mass was identified as a retinal vasoproliferative tumor (RVT) with clearly defined afferent and efferent vessels.
a Retinography shows the presence of the Ozurdex  device 1 week after its implantation. b Horizontal OCT scan and 3-dimensional reconstruction (c) show the presence of the implant adjacent to the retinal vasoproliferative tumor.
cop-0003-0123-g02.jpg
PMC3339664_01_cop-0003-0123-g02.jpg
F2
Ozurdex  (Allergan, Inc., Irvine, Calif., USA). One week later, her BCVA improved to 20/40 and SD-OCT revealed a complete resolution of the exudative retinal detachment (fig. 2).
Retinography after 12 months of follow-up reveals regression of lipid exudation and retinal scars from photocoagulation.
cop-0003-0123-g03.jpg
PMC3339664_01_cop-0003-0123-g03.jpg
F3
One year after initial treatment with intravitreal Ozurdex, the patient's BCVA was 20/25 (fig. 3).